HERCULES, CA – February 22, 2010 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multi-national manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of Liquichek™ Hematology Control (A-I) and Liquichek Reticulocyte Control (A-I). These two new products are designed to monitor the precision of hematology parameters on Abbott CELL-DYN Sapphire® and CELL-DYN® 4000 systems.
The Unity™ Interlaboratory Program, with peer group comparison, is available for use with Liquichek Hematology (A-I) and Liquichek Reticulocyte Control (A-I). Data entry to the Unity software can be conveniently automated with UnityConnect™ or WebConnect™ connectivity solutions.
Liquichek Hematology Control (A-I) is available in three levels, with a 75 day shelf life and 8 day open-vial stability. Liquichek Reticulocyte Control (A-I) is available in two levels, with a 75 day shelf life and 14 day open-vial stability. Samples are available upon request.
For more information, please call 1-800-2-BIORAD (1-800-224-6723) or visit
www.bio-rad.com/diagnostics.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,700 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements..
For more information contact:
Lily Sunkin, Product Manager
Bio-Rad Laboratories, Inc.
949-598-1244
Email: lily_sunkin@bio-rad.com